Viking Therapeutics Sets Ambitious Clinical Trial Timeline for 2026
Published on 03/28/2026 at 10:08 | Redaktion boerse-global.de
Market confidence in Viking Therapeutics received a significant boost in late February when BTIG Research upgraded the biopharmaceutical company to a "Strong Buy" rating. This move was strategically timed, coinciding with the company's announcement that it had completed patient enrollment for its pivotal VANQUISH-2 Phase 3 clinical trial.
A Robust Late-Stage Pipeline Takes Shape
The company’s clinical development strategy is centered on VK2735, a dual GLP-1 and GIP receptor agonist. The recently filled VANQUISH-2 study is evaluating a subcutaneous formulation of this drug candidate. It involves approximately 1,000 adult participants who have been diagnosed with type 2 diabetes alongside obesity or overweight. This randomized, double-blind, and placebo-controlled trial is scheduled to run for 78 weeks.
With the earlier VANQUISH-1 trial having finished recruitment at the end of 2025, Viking Therapeutics now has both of its key registration studies on track. Top-line results from these trials are anticipated in 2027.
Looking ahead, CEO Brian Lian has outlined an aggressive plan for the remainder of 2026. The company intends to initiate a Phase 3 study for an oral formulation of VK2735 in the third quarter. Concurrently, initial data readouts are expected from a Phase 1 trial exploring various maintenance dosing regimens, which include monthly injections and a daily oral tablet. By the close of 2026, Viking aims to be managing four concurrent late-stage clinical studies.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Financial Health and Analyst Sentiment
The firm’s financial position appears solid, with a current ratio of 9.33 and a market capitalization hovering around $3.84 billion. This stability underpins the optimistic outlook shared by several equity research firms.
Analyst price targets reflect substantial confidence in the company's pipeline. Raymond James maintains its "Strong Buy" recommendation with a $118 target. Similarly, Jefferies and Truist Securities have reaffirmed their buy ratings, setting price objectives of $101 and $75 per share, respectively. The market responded positively to the VANQUISH-2 enrollment completion, with Viking's stock advancing approximately 3% on the day of the announcement.
In a separate corporate development, Vanguard reported an internal restructuring of its holdings on March 27. Due to a reclassification following SEC guidelines, various Vanguard subsidiaries will now report their positions in Viking Therapeutics separately rather than as a consolidated block. This is described as a purely administrative change with no material impact on the overall ownership structure.
Viking Therapeutics at a turning point? This analysis reveals what investors need to know now.
The immediate focus for investors will be the planned launch of the oral VK2735 Phase 3 trial in Q3 2026, marking the next significant milestone for the clinical-stage company.
Ad
Viking Therapeutics Stock: New Analysis - 28 March
Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
